Browsing by Subject Vaccines

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  

Showing results 1 to 20 of 1077  next >
14th meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE).pdf.jpg
14th meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE)
( 2014 )
Abstract

The European Technical Advisory Group of Experts on Immunization (ETAGE) met on 8–9 October 2014 to review and discuss immunization activities and developments in the WHO European Region and provide advice to the WHO Regional Office on appropriate activities. Main topics for discussion included the measles and rubella action plan and progress made in achieving the regional elimination goal; monitoring implementation of the Global Vaccine Action Plan (GVAP) and development of the European Vaccine Action Plan 2015–2020 (EVAP); defining a regional goal for hepatitis B control; an update on the Strategic Advisory Group of Experts on Immunization (SAGE) Pertussis Working Group activities; and updates on Vaccine Safety Communication, Advocacy initiatives, IPV introduction as part of the polio endgame strategy, and National Immunization Technical Advisory Group (NITAG) strategic activities.

WHO_EPI_LHIS_94.5.pdf.jpg
1995 [Nineteen ninety-five] EPI cold chain bibliography
WHO Expanded Programme on Immunization ( 1994 )
WHO_VRD_GEN_95.03.pdf.jpg
1995 [Nineteen ninety-five] progress report and plan of activities for 1996, including full report of the Research and Development Subgroup Session of the Meeting of the Scientific Advisory Group of Experts (SAGE, 12-14 June 1995
WHO Global Programme for Vaccines and Immunization. Scientific Advisory Group of Experts. Research and Development Subgroup. Session . Meeting; WHO Global Programme for Vaccines and Immunization ( 1995 )
WHO_TRS_747_fre.pdf.jpg
Acceptabilité des substrats cellulaires pour la production de substances biologiques : rapport d'un Groupe d' étude de l' OMS [réuni à Genève, 18-19 novembre 1986]
WHO Study Group on Biologicals; World Health Organization ( 1987 )
Abstract

Analyse succincte mais très intéressante des problèmes liés à l'utilisation de cellules eucaryotes et procaryotes pour la production de substances biologiques. L'accent est mis sur l'évaluation des risques potentiels liés à une contamination par des virus de l'ADN. Deux principaux types de problèmes sont envisagés : premièrement, est-il acceptable de produire une substance biologique dans un nouveau système cellulaire lorsque la même substance générique est déjà fabriquée par une méthode agréée et deuxièmement, quel est le degré de risque associé à la présence de certaines catégories de contaminants possibles dans le produit. Ces contaminants comprennent l'ADN hétérogène, les virus et les protéines transformantes. Pour chaque contaminant, le rapport décrit et analyse les risques potentiels pour l'être humain et le cas échéant, classe ces risques en catégories. Il recommande également des principes fondamentaux de fabrication et d'essai pouvant contribuer à minimiser les risques pour les receveurs humains de produits obtenus en lignées cellulaires continues

WHO_TRS_747.pdf.jpg
Acceptability of cell substrates for production of biologicals : report of a WHO study group [meeting held in Geneva from 18 to 19 November 1986]
WHO Study Group on Biologicals; World Health Organization ( 1987 )
Abstract

A brief yet highly significant analysis of issues associated with the use of eukaryotic and prokaryotic cells in the production of biologicals. The report considers two main types of issues: first, the acceptability of developing a biological product in a new cell system when the same generic product is already being manufactured by an approved method, and second, the degree of risk associated with certain classes of possible contaminants in the product. These include heterogeneous contaminating DNA, viruses, and transforming poteins. For each contaminant, the report describes and analyses the potential risks to humans and, where appropriate, categorizes and classifies these risks. The report also advocates basic principles of manufacturing and testing that can help minimize the likelihood of risks to human recipients of products manufactured in continuous cell lines

WHO_TRS_747_spa.pdf.jpg
Aceptabilidad de los sustratos celulares para la producci'on de sustancias biol'ogicas : informe de un Grupo de Estudio de la OMS [se reuni'o en Ginebra, 18-19 de noviembre de 1986]
WHO Study Group on Biologicals; World Health Organization ( 1987 )
WHA37_R32_eng.pdf.jpg
Action programme on essential drugs and vaccines
World Health Assembly, 37 ( 1984 )
WPR_RC036_Res09_1985_en.pdf.jpg
Action programme on essential drugs and vaccines (Resolution)
Regional Committee for the Western Pacific, 036 ( 1985 )
EB73_R15_eng.pdf.jpg
Action programme on essential drugs and vacines
Executive Board, 73 ( 1984 )
EB73_Conf.Paper-8_eng.pdf.jpg
Action programme on essential drugs and vacines (draft resolution proposed by the chairman of the ad hoc committee and the rapporteurs)
Executive Board, 73 ( 1984 )
EB73_18_eng.pdf.jpg
Action programme on essential drugs and vacines: progress report by the Executive Board Ad Hoc Committee on Drug Policies
Executive Board, 73 ( 1984 )
A67_3-en.pdf.jpg
Address by Dr Margaret Chan, Director-General, to the Sixty-seventh World Health Assembly
World Health Assembly, 67 ( 2014 )
A67_DIV6-en.pdf.jpg
Address by Melinda Gates, Bill & Melinda Gates Foundation, to the Sixty-seventh World Health Assembly: Geneva, Tuesday, 20 May 2014
World Health Assembly, 67 ( 2014 )
A64_DIV6-en.pdf.jpg
Address by Mr. Bill Gates to the Sixty-fourth World Health Assembly
World Health Assembly, 64 ( 2011 )
WHO_V-B_02.32_eng.pdf.jpg
Adopting global vaccine management policies for national use
World Health Organization. Dept. of Vaccines and Biologicals ( 2002 )
wer7828.pdf.jpg
Adoption du vaccin antipoliomyélitique inactivé par les pays utilisant le vaccin antipoliomyélitique oral
( 2003 )
Adverse drug reaction monitoring : new issues : general policy issues
( 1997 )
bu0846.pdf.jpg
Adverse events monitoring as a routine component of vaccine clinical trials : evidence from the WHO Vaccine Trial Registry : feedback / Marti Vall Mayans, Susan E. Robertson, Philippe Duclos
Vall Mayans, Marti; Robertson, Susan E; Duclos, Philippe ( 2000 )
WHO_IVB_07.09_eng.pdf.jpg
Aide mémoire for prevention of freeze damage to vaccines
World Health Organization. Dept. of Vaccines and Biologicals ( 2007 )
ser4.pdf.jpg
Alianza Mundial para Vacunas e Inmunización
Consejo Ejecutivo, 105 ( 2000 )
Showing results 1 to 20 of 1077  next >